US Stock Insider Trading | Sera Prognostics disclosed 8 insider trading transactions on March 12

K-LinePoet · 2026-04-11T02:03:36+00:00

Sera Prognostics disclosed insider trading activities on March 12, 2026, including multiple executives such as Director Lindgardt Zhenya conducting stock sales on March 10 and 11, involving large quantities and amounts. The company focuses on women's health diagnostics, aiming to improve maternal health through biomarker testing.

K-LinePoet

2026-04-11 02:03:36

Abstract generation in progress

On March 12, 2026, Sera Prognostics (SERA) disclosed eight insider trading transactions. Director Zhenya Lindgardt sold 22,700 shares on March 11, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 12, 2026	Executive	Harrison Robert Gardner	March 11, 2026	Sell	716	2.04	1,460.64
March 12, 2026	Executive	Jackson Benjamin	March 11, 2026	Sell	1,027	2.04	2,095.08
March 12, 2026	Executive	Aerts Austin	March 10, 2026	Sell	6,069	1.90	$11.5k
March 12, 2026	Executive	Aerts Austin	March 11, 2026	Sell	1,019	2.04	2,078.76
March 12, 2026	Director	Lindgardt Zhenya	March 11, 2026	Sell	2,973	2.04	6,064.92
March 12, 2026	Executive	Boniface John J.	March 11, 2026	Sell	1,517	2.04	3,094.68
March 12, 2026	Director	Lindgardt Zhenya	March 10, 2026	Sell	22.6k	1.90	43k
March 12, 2026	Executive	Kearney Paul	March 11, 2026	Sell	1,396	2.04	2,847.84
March 10, 2026	Executive	Boniface John J.	March 9, 2026	Sell	3,038	1.96	5,954.48
March 10, 2026	Executive	Jackson Benjamin	March 9, 2026	Sell	3,119	1.96	6,113.24

【Company Information】

Sera Prognostics, Inc. was incorporated on January 17, 2008, under the laws of Delaware. The company is a women’s health diagnostics company that leverages its proprietary proteomics and bioinformatics platform to discover, develop, and commercialize biologically and economically meaningful biomarker tests, initially focusing on improving pregnancy outcomes. The company’s vision is to provide key and actionable information to pregnant women, physicians, and healthcare payers to significantly improve maternal and neonatal health and substantially reduce healthcare costs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.